Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia
NCT: NCT04352569 · COMPLETED
Brief Summary
The regions which are assumed to underlie the pathophysiology of schizophrenia, namely hypoactivity at the prefrontal level and pathological hyperactivity of the associative regions of the language located in the left temporoparietal region. To assess the efficacy of tDCS on auditory hallucinations, the investigators performs an randomized double blind versus placebo trial. In each arms patients will receive two tDCS sessions a day during two weeks.
Frequently Asked Questions
What is Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia?
Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia is a clinical trial registered under NCT04352569. Current status: COMPLETED.
What is the status of NCT04352569?
The current status of NCT04352569 (Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia) is: COMPLETED.
When did Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia start?
Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia started on 2016-05-03.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.